About
Nuvaira, Inc. is a medical device company based in Minneapolis, Minnesota, founded in 2008. The company focuses on developing therapies for obstructive lung diseases, particularly Chronic Obstructive Pulmonary Disease (COPD) and asthma. Nuvaira aims to enhance patient outcomes for the millions affected by these conditions. The company's primary product is the dNerva® Lung Denervation System, a catheter-based technology that treats overactive airway nerves through a one-time outpatient procedure called Targeted Lung Denervation (TLD). This innovative therapy seeks to disrupt nerve signals to the lungs, helping to preserve lung health, reduce exacerbations, and improve breathlessness. The dNerva system has shown clinical benefits, including a lower risk of severe exacerbations and stable lung function over time. Nuvaira holds over 70 patents worldwide, showcasing its commitment to innovation in respiratory medicine. The leadership team includes experienced professionals dedicated to addressing the needs of patients with obstructive lung diseases.
Technologies
Keywords
Company Information
-
Employees 17
-
Founded 2008
-
Annual Revenue $61111000
-
Total Funding $168494603
Location
6500 Wedgwood Rd N, Maple Grove, Minnesota, United States, 55311-3605